at://
/
app.bsky.feed.post
/
3mnx3g7cqyq24
sign in
All
4
Record
2
Post
1
PostEmbed
1
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Update: #EULAR2026 late-breaking results from the Phase 1 study of CLN-978 show clinical benefit after a single target dose in people with refractory systemic #lupus erythematosus. Read the announcement: buff.ly/6GO2dmW
1d
Lupus Foundation of America
